Patrick Finn

USPTO Granted Patents = 11 (Patent Applications = 6)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 8.7

ph-index = 4

Forward Citations = 30(Granted Patents)

Location History:

Weymouth, MA (US) (2014 - 2022)
Franklin, MA (US) (2020 - 2024)

Company Filing History:

Years Active: 2014-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12252504 - Oligosaccharide-protein conjugates (2025-03-18),

2. 12251430 - Compositions and methods for treating Pompe disease (2025-03-18),

3. 12049496 - Anti-TGF-beta antibodies and their use (2024-07-30),

4. 11939601 - Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria (2024-03-26),

5. 11859215 - Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders (2024-01-02),

6. 11279725 - Oligosaccharide-protein conjugates (2022-03-22),

7. 11242384 - Anti-TGF-beta antibodies and their use (2022-02-08),

8. 10766955 - Anti-TGF-β antibodies and their use (2020-09-08),

9. 10464962 - Oligosaccharide-protein conjugates (2019-11-05),

10. 9493498 - Oligosaccharide-protein conjugates (2016-11-15),

11. 8835614 - Oligosaccharide-protein conjugates (2014-09-16),

Title: Innovator Patrick Finn: Pioneering Treatments for Pompe Disease

Introduction

Patrick Finn, an accomplished inventor based in Franklin, MA, has made significant contributions to the field of medical innovation with a focus on treatments for lysosomal storage disorders. With a remarkable tally of 11 patents to his name, his work is advancing novel therapies aimed at improving patient outcomes.

Latest Patents

Among his latest contributions, Finn has developed groundbreaking patents related to compositions and methods for treating Pompe disease, specifically infantile-onset Pompe disease (IOPD). His application presents a pharmaceutical composition featuring an oligosaccharide-acid α-glucosidase (GAA) conjugate known as avalglucosidase alfa. Furthermore, he has provided formulations of these oligosaccharide-GAA conjugates, enhancing treatment efficacy. Another significant patent involves oligosaccharide-protein conjugates, which comprise a protein alongside oligosaccharides, thus creating pharmaceutical compositions that promise to treat lysosomal storage disorders effectively.

Career Highlights

Finn's professional journey includes notable tenures at leading companies in the biotechnology field, such as Genzyme Corporation and Sanofi. His roles at these organizations have allowed him to leverage his expertise, contributing to advancements in biopharmaceuticals and therapies targeting complex genetic disorders.

Collaborations

Throughout his career, Patrick Finn has collaborated with notable colleagues, including Luis Z Avila and Clark Qun Pan. These partnerships have fostered an environment of shared knowledge and innovation, essential for advancing treatment options in the medical field.

Conclusion

Patrick Finn exemplifies the spirit of innovation in healthcare, with his patents reflecting a deep commitment to addressing unmet medical needs. His work in developing treatments for Pompe disease is crucial, signaling progress in therapeutic options for patients affected by this challenging condition. As he continues to innovate, Finn remains a vital figure in the evolution of medical treatments.

This text is generated by artificial intelligence and may not be accurate.